Hepatic Steatosis clinical trials

Explore recruiting hepatic steatosis clinical trials.

Recruiting hepatic steatosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hepatic Steatosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Pilot Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2b/3 Randomized Open-Label Dose-Selection Study with Open-Label Extension and Randomized Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Safety and Efficacy of Choline Chloride for Injection (Low Dose and High Dose) Versus Placebo in Adolescents and Adults with Intestinal Failure Receiving Long-Term Parenteral Support

France, Denmark, Germany, Belgium, Poland

Phase II and Phase III (Integrated) EU CTIS Study details

A Double-Blind, Placebo-Controlled, Crossover Pilot Study of the Efficacy and Safety of Fluasterone Buccal Tablet in the Control of Hyperglycemia in Adults with Endogenous Cushing’s Syndrome

Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

SPI-62 as a Treatment for Adrenocorticotropic Hormone- dependent Cushing’s Syndrome

Bulgaria, Romania

Therapeutic exploratory (Phase II) EU CTIS Study details

Open-label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or hypertriglyceridaemia

Italy, Germany, Belgium, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orziloben (NST-6179) in Subjects with Intestinal Failure-Associated Liver Disease (IFALD)

Belgium, Denmark, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Hepatic Steatosis trials by city

Hepatic Steatosis in Toronto Hepatic Steatosis in Vancouver Hepatic Steatosis in Montreal Hepatic Steatosis in Calgary Hepatic Steatosis in Edmonton Hepatic Steatosis in Ottawa Hepatic Steatosis in Winnipeg Hepatic Steatosis in Quebec City Hepatic Steatosis in Hamilton Hepatic Steatosis in Kitchener Hepatic Steatosis in London Hepatic Steatosis in Halifax Hepatic Steatosis in New York Hepatic Steatosis in Los Angeles Hepatic Steatosis in Chicago Hepatic Steatosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease